论文部分内容阅读
乳腺癌新辅助化疗在临床运用已有30多年,具有控制疾病进展、降低肿瘤分期和提高保乳率等优点[1]。美国国立外科辅助乳腺和大肠项目组(National Surgical Adjuvant Breast Project,NSABP)B-18[2]大型临床试验证实,新辅助化疗中获得临床部分反应(pCR)的患者,其无病生存期(DFS)
Neoadjuvant chemotherapy for breast cancer has been used clinically for over 30 years and has the advantages of controlling disease progression, reducing tumor staging, and increasing the rate of breast-conserving milk [1]. Large-scale clinical trials in the National Surgical Adjuvant Breast Project (NSABP) B-18 2 confirmed that patients with clinicallysignificant response (pCR) in neoadjuvant chemotherapy had a disease-free survival (DFS) )